Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammation
Biotech
Neurocrine pens $880M pact with TransThera for immunology target
San Diego-based Neurocrine secured the rights to develop and commercialize preclinical NLRP3 inhibitors.
James Waldron
Nov 3, 2025 5:42am
Biogen pens $1B deal for Vanqua's preclinical C5aR1 antagonist
Oct 24, 2025 9:15am
HCW Biologics clings on with $5M lifeline to fund alopecia trial
May 16, 2025 7:00am
Gilead roars into JPM25 with $250M upfront deal for Leo
Jan 11, 2025 5:30pm
Celldex drops phase 1 tumor bispecific to focus on inflammation
Nov 7, 2024 7:25am
Ocean Biomedical pens $32M pact for Polish YKL-40 inhibitors
Oct 15, 2024 10:05am
